-
1.发明申请QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS 审中-公开喹啉化合物作为ALPHA-7非丁醇乙酰胆碱受体配体公开(公告)号：US20150094309A1
公开(公告)日：2015-04-02
申请号：US14574653
申请日：2014-12-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor
IPC: C07D519/00
CPC classification number: A61K31/506 , A61K31/439 , C07D498/20 , C07D519/00
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是烟碱型α7受体的配体，可用于治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病。
-
公开(公告)号：US08841301B2
公开(公告)日：2014-09-23
申请号：US13625015
申请日：2012-09-24
Applicant: Bristol-Myers Squibb Company
Inventor： Dalton King , John E. Macor , Richard E. Olson , Christiana I. Iwuagwu , George N. Karageorge
IPC: C07D403/12 , C07D413/12 , A61K31/536 , A61K31/4709
CPC classification number: C07D401/12 , C07D239/42 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
Patent Agency Ranking
公开(公告)号：US10398783B2
公开(公告)日：2019-09-03
申请号：US15789027
申请日：2017-10-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ivar M. McDonald , Prasanna Sivaprakasam , Christiana I. Iwuagwu , Kevin M. Peese , Heng Cheng , Naidu S. Chowdari , Sanjeev Gangwar
IPC: C07D471/04 , A61K47/68 , C07D519/00 , C07F7/08 , C07K5/062
Abstract: A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.
-
公开(公告)号：US20150342935A1
公开(公告)日：2015-12-03
申请号：US14820412
申请日：2015-08-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor
IPC: A61K31/439
CPC classification number: A61K31/506 , A61K31/439 , C07D498/20 , C07D519/00
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
-
5.发明申请Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands 审中-公开奎宁环化合物作为α-7烟碱乙酰胆碱受体配体公开(公告)号：US20140221377A1
公开(公告)日：2014-08-07
申请号：US14246566
申请日：2014-04-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor
IPC: C07D498/20
CPC classification number: A61K31/506 , A61K31/439 , C07D498/20 , C07D519/00
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是烟碱型α7受体的配体，可用于治疗中枢神经系统的各种疾病，特别是情感和神经变性疾病。
-
6.发明申请Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands 审中-公开奎宁环化合物作为α-7烟碱乙酰胆碱受体配体公开(公告)号：US20130131064A1
公开(公告)日：2013-05-23
申请号：US13740390
申请日：2013-01-14
Applicant: Bristol-Myers Squibb Company
Inventor： James H. Cook, II , Ivar M. McDonald , Dalton King , Richard E. Olson , Nenghui Wang , Christiana I. Iwuagwu , F. Christopher Zusi , John E. Macor
IPC: C07D498/20
CPC classification number: A61K31/506 , A61K31/439 , C07D498/20 , C07D519/00
Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Abstract translation: 本公开提供式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是烟碱型α7受体的配体，可用于治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病。
-
公开(公告)号：US20130079338A1
公开(公告)日：2013-03-28
申请号：US13625015
申请日：2012-09-24
Applicant: Bristol-Myers Squibb Company
Inventor： Dalton King , John E. Macor , Richard E. Olson , Christiana I. Iwuagwu , George N. Karageorge
IPC: C07D401/12 , C07D239/22 , A61K31/506 , C07D403/12 , A61P25/16 , A61K31/536 , A61P25/24 , A61P25/28 , A61P25/00 , A61K31/4709 , C07D413/12
CPC classification number: C07D401/12 , C07D239/42 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
-
-
-
-
-
-
Search Results
7
records
(took 0.046 seconds)
